Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene

Riccardo Masetti, Salvatore Nicola Bertuccio, Annalisa Astolfi, Francesca Chiarini, Annalisa Lonetti, Valentina Indio, Matilde De Luca, Jessica Bandini, Salvatore Serravalle, Monica Franzoni, Martina Pigazzi, Alberto Maria Martelli, Giuseppe Basso, Franco Locatelli, Andrea Pession

Research output: Contribution to journalArticle

Abstract

Background: CBFA2T3-GLIS2 is a fusion gene found in 17% of non-Down syndrome acute megakaryoblastic leukemia (non-DS AMKL, FAB M7) and in 8% of pediatric cytogenetically normal acute myeloid leukemia (CN-AML, in association with several French-American-British (FAB) subtypes). Children with AML harboring this aberration have a poor outcome, regardless of the FAB subtype. This fusion gene drives a peculiar expression pattern and leads to overexpression of some of Hedgehog-related genes. GLI-similar protein 2 (GLIS2) is closely related to the GLI family, the final effectors of classic Hedgehog pathway. These observations lend compelling support to the application of GLI inhibitors in the treatment of AML with the aberration CBFA2T3-GLIS2. GANT61 is, nowadays, the most potent inhibitor of GLI family proteins. Methods: We exposed to GANT61 AML cell lines and primary cells positive and negative for CBFA2T3-GLIS2 and analyzed the effect on cellular viability, induction of apoptosis, cell cycle, and expression profile. Results: As compared to AML cells without GLIS2 fusion, GANT61 exposure resulted in higher sensitivity of both cell lines and primary AML cells carrying CBFA2T3-GLIS2 to undergo apoptosis and G1 cell cycle arrest. Remarkably, gene expression studies demonstrated downregulation of GLIS2-specific signature genes in both treated cell lines and primary cells, in comparison with untreated cells. Moreover, chromatin immunoprecipitation analysis revealed direct regulation by GLIS2 chimeric protein of DNMT1 and DNMT3B, two genes implicated in important epigenetic functions. Conclusions: Our findings indicate that the GLI inhibitor GANT61 may be used to specifically target the CBFA2T3-GLIS2 fusion gene in pediatric AML.
Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalJournal of Hematology and Oncology
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 21 2017

Keywords

  • Acute megakaryoblastic leukemia
  • Acute myeloid leukemia
  • CBFA2T3-GLIS2
  • GANT61
  • Hedgehog pathway

Fingerprint Dive into the research topics of 'Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene'. Together they form a unique fingerprint.

  • Cite this

    Masetti, R., Bertuccio, S. N., Astolfi, A., Chiarini, F., Lonetti, A., Indio, V., De Luca, M., Bandini, J., Serravalle, S., Franzoni, M., Pigazzi, M., Martelli, A. M., Basso, G., Locatelli, F., & Pession, A. (2017). Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. Journal of Hematology and Oncology, 10(1), 1-5. https://doi.org/10.1186/s13045-017-0396-0